Procurement Summary
Country : USA
Summary : Continuous Ketone Monitoring for the Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in Type 1 Diabetes (r01 Clinical Trial Required)
Deadline : 27 Jun 2024
Other Information
Notice Type : Tender
TOT Ref.No.: 96075680
Document Ref. No. : RFA-DK-23-011
Competition : ICB
Financier : Self Financed
Purchaser Ownership : Public
Tender Value : Refer Document
Purchaser's Detail
Name :Login to see tender_details
Address : Login to see tender_details
Email : Login to see tender_details
Login to see detailsTender Details
Sodium-Glucose Co-Transporter-2 Inhibitors (Sglt2I) That Were Developed For The Treatment Of Type 2 Diabetes (T2D) Have Significant Protective Effects For Cardiac And Renal Diseases For People With And Without Diabetes. However, Sglt2I Are Not Currently Approved For Individuals With Type 1 Diabetes (T1D) And There Is An Increased Risk Of Diabetic Ketoacidosis (Dka) For This Population. Despite This Concern, These Drugs Are Increasingly Being Prescribed Off-Label For People With T1D. Continuous K...
Opportunity Category : Discretionary
Opportunity Category Explanation :
Funding Instrument Type : Grant
Category of Funding Activity : Food and NutritionHealth
CFDA_Number : 93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research
Award_Ceiling : 500000
Posted Date : Jan 30, 2024
Last Updated Date : Jan 30, 2024
Documents
Tender Notice